[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Charfi S, Krichen-Makni S, Yaich S, Makni H, Khabir A, Amouri A, Charfeddine K, Hachicha J, Sellami-Boudawara T: Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment. Saudi J Kidney Dis Transpl; 2007 Nov;18(4):617-20
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
  • The incidence of Kaposi's sarcoma (KS) is higher in organ transplant recipients.
  • Computed tomography of the chest revealed multiple bilateral lung micronodules.
  • This resulted in a regression of both stomach and pulmonary KS.
  • One-year later, the patient developed an episode of acute rejection, which was successfully treated with bolus steroids.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Kidney Transplantation / adverse effects. Lung Neoplasms / drug therapy. Sarcoma, Kaposi / drug therapy. Sirolimus / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Endoscopy, Gastrointestinal. Follow-Up Studies. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951954.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


2. Bryant AE, Genc M, Hurtado RM, Chen KT: Pulmonary Kaposi's sarcoma in pregnancy. Am J Perinatol; 2004 Aug;21(6):355-63
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary Kaposi's sarcoma in pregnancy.
  • Kaposi's sarcoma in human immunodeficiency virus (HIV) -infected women, often misdiagnosed, has an aggressive clinical course, with high rates of visceral involvement and decreased survival.
  • We describe the first case of isolated pulmonary Kaposi's sarcoma in pregnancy.
  • A nulliparous woman was diagnosed with AIDS after presenting at 25 weeks gestation with a cough and multiple pulmonary nodules.
  • Extensive pulmonary evaluation was nondiagnostic until thorascopic lung biopsy revealed Kaposi's sarcoma.
  • Despite combination antiretroviral therapy, her malignancy progressed.
  • She received chemotherapy postpartum and remains in remission.
  • Pulmonary Kaposi's sarcoma should be considered in the differential diagnosis of HIV-infected obstetric patients with respiratory compromise.
  • Definitive diagnosis is necessary given the aggressive clinical course that is potentially responsive to therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lung Neoplasms / diagnosis. Pregnancy Complications, Infectious / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy. Time Factors


3. Krayem AB, Abdullah LS, Raweily EA, Wali SO, Rawas MM, Samman YS, Batouk AA: The diagnostic challenge of pulmonary Kaposi's sarcoma with pulmonary tuberculosis in a renal transplant recipient: a case report. Transplantation; 2001 May 27;71(10):1488-91
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic challenge of pulmonary Kaposi's sarcoma with pulmonary tuberculosis in a renal transplant recipient: a case report.
  • We report a case of a 39-year-old, HIV-negative, post renal transplant patient who developed mucocutaneous Kaposi's sarcoma with lung parenchymal involvement and concurrently culture proven pulmonary tuberculosis.
  • To the best of our knowledge, this is the first case report of this combination, which presented with cavitating lung nodules and responded well to withdrawal of immunosuppressive drugs beside antituberculous treatment.
  • [MeSH-major] Kidney Transplantation. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Drug Therapy, Combination. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11391242.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


Advertisement
4. Chakib A, Hliwa W, Marih L, Himmich H: [Kaposi's sarcoma during HIV infection in Morocco (apropos of 50 cases)]. Bull Soc Pathol Exot; 2003 May;96(2):86-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma during HIV infection in Morocco (apropos of 50 cases)].
  • [Transliterated title] Maladie de Kaposi au cours de l'infection par le VIH au Maroc. (A propos de 50 cas).
  • Kaposi's sarcoma is the most common neoplasm to be found among AIDS patients.
  • The purpose of this retrospective study is to determine the epidemiological, clinical, therapeutic features and the evolution of Kaposi's sarcoma in Moroccan patients suffering from AIDS.
  • Fifty of them (7%) had Kaposi's sarcoma.
  • The diagnosis of Kaposi's sarcoma was established by clinical aspect and I or by histologically study.
  • AIDS was revealed by Kaposi's sarcoma in 82% of cases.
  • The Lesions were found in the skin (96%), in the skin and mucous membranes (56%), in the lung (14%), in the gastrointestinal tract (12%) and in the lymphatic nodes (8%).
  • The chemotherapy was instituted in 43 patients and the radiotherapy in 5 patients (alone or associated with chemotherapy).
  • Six patients didn't received any treatment.
  • This death was due to Kaposi's sarcoma in six patients and to opportunistic infections in the others cases.
  • Our study demonstrates the high incidence of Kaposi's sarcoma as an inaugurating event of AIDS, the severity of the visceral involvement, the limit of our therapeutic materials and the wrong prognosis of this disease.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cause of Death. Female. Humans. Male. Middle Aged. Morocco / epidemiology. Radiotherapy. Retrospective Studies

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12836521.001).
  • [ISSN] 0037-9085
  • [Journal-full-title] Bulletin de la Société de pathologie exotique (1990)
  • [ISO-abbreviation] Bull Soc Pathol Exot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Davis JL, Shum AK, Huang L: A 36-year-old man with AIDS and relapsing, nonproductive cough. Chest; 2007 Jun;131(6):1929-31
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rapidly progressive, fatal recrudescence of pulmonary Kaposi sarcoma developed in an HIV-infected man who was receiving corticosteroids for treatment of an immune reconstitution syndrome secondary to Mycobacterium avium complex pulmonary infection.
  • We discuss the implications for current diagnosis and management of HIV-associated pulmonary diseases.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Acquired Immunodeficiency Syndrome / complications. Mycobacterium avium-intracellulare Infection / complications. Mycobacterium avium-intracellulare Infection / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Adult. Anti-Retroviral Agents / adverse effects. Anti-Retroviral Agents / therapeutic use. Cough / etiology. Fatal Outcome. Humans. Lung / microbiology. Lung / pathology. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Male. Mycobacterium avium Complex / pathogenicity. Recurrence. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / drug therapy


6. Aboulafia DM: The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest; 2000 Apr;117(4):1128-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma.
  • AIDS-related Kaposi's sarcoma (KS) occurs principally in homosexual or bisexual men infected with the newly identified human herpes virus-8, also called KS-associated herpes virus.
  • KS may also occur in the lung, commonly in the setting of extensive mucocutaneous disease and very rarely as an isolated event.
  • Before the advent of highly active antiretroviral therapy (HAART), pulmonary KS had been reported in approximately 10% of patients with AIDS, 25% of patients with cutaneous KS, and in roughly 50% of postmortem examinations of patients with AIDS, KS, and respiratory infections.
  • Pulmonary KS may cause radiographic infiltrates and respiratory symptoms that mimic a variety of other infectious and neoplastic processes.
  • An aggressive diagnostic evaluation of patients who have this condition is essential because chemotherapy and radiation therapy may provide significant palliation, particularly if used in conjunction with HAART.
  • The pathology and pathogenesis of KS is also reviewed, along with the clinical and radiographic presentation, diagnosis, and management of pulmonary KS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Herpesvirus 8, Human. Lung Neoplasms. Sarcoma, Kaposi


7. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A: Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol; 2001 Sep 15;19(18):3848-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy.
  • PURPOSE: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy.
  • Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months.
  • We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS.
  • The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause.
  • RESULTS: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART.
  • Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69).
  • CONCLUSION: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Lung Neoplasms / complications. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Ethnic Groups. Humans. Middle Aged. Multivariate Analysis. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome


8. Duman S, Töz H, Aşçi G, Alper S, Ozkahya M, Unal I, Celik A, Ok E, Başçi A: Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant; 2002 May;17(5):892-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.
  • BACKGROUND: The aim of this study was to investigate retrospectively the clinical presentation, the efficacy of reducing immunosuppression and the consequences of this therapeutic approach in Kaposi's sarcoma (KS) developing after renal transplantation.
  • All were on prednisone, azathioprine (AZT) and cylcosporin treatment.
  • Typical Kaposi's lesions were present in the skin of 11 out of l2 patients.
  • In five patients only skin involvement was present, while the others also had visceral involvement (oropharynx in two patients, trachea and lung in three, lymph node in two, stomach and duodenum in two).
  • Cyclosporin was stopped within 1 month after KS diagnosis, and AZT was stopped in three patients.
  • During a follow-up period 46+/-19 months, KS recurred in the lungs in one patient together with lung tuberculosis, while he was on prednisone and AZT.
  • Reduction or discontinuation of immunosuppression caused complete remission in all patients without surgical intervention, chemotherapy or radiotherapy.
  • [MeSH-major] Immunosuppressive Agents / administration & dosage. Kidney Transplantation / adverse effects. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / therapy. Skin Neoplasms / etiology. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981080.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


9. Dufour V, Cadranel J, Wislez M, Lavole A, Bergot E, Parrot A, Rufat P, Mayaud C: Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy. Lung; 2004;182(6):331-41
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy.
  • The incidence rates of opportunistic diseases, hospital admission and death have fallen markedly since the advent of highly active antiretroviral therapy (HAART).
  • Pulmonary opportunistic infections other than Pneumocystis carinii pneumonia (PCP) (p = 0.0008) and exacerbations of chronic bronchial disease due to gram-negative bacilli (p = 0.04) virtually disappeared in era 2.
  • In contrast, PCP, bacterial pneumonia, tuberculosis, pulmonary Kaposi's sarcoma and pulmonary non-Hodgkin lymphoma showed only a twofold decrease in era 2, while lung cancer was more frequent (p = 0.004).
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Respiratory Tract Diseases / epidemiology. Respiratory Tract Infections / epidemiology
  • [MeSH-minor] Adult. Data Collection. Female. Hospitalization / statistics & numerical data. Humans. Incidence. Lung Neoplasms / epidemiology. Male. Paris / epidemiology. Pneumonia, Pneumocystis / epidemiology. Retrospective Studies. Risk Factors. Sarcoma, Kaposi / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1998 Dec;27(6):1379-85 [9868646.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1725-30 [9848347.001]
  • [Cites] Am Rev Respir Dis. 1989 Dec;140(6):1763-87 [2690709.001]
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S44-8 [8547511.001]
  • [Cites] N Engl J Med. 1997 May 22;336(21):1531-2 [9157292.001]
  • [Cites] Chest. 1997 Jan;111(1):128-34 [8996006.001]
  • [Cites] AIDS. 1997 Nov 15;11(14):1731-8 [9386808.001]
  • [Cites] Thorax. 1993 Mar;48(3):204-7 [8497816.001]
  • [Cites] MMWR Recomm Rep. 1999 Aug 20;48(RR-10):1-59, 61-6 [10499670.001]
  • [Cites] Thorax. 2000 Jul;55(7):625-7 [10856327.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):418-25 [14727215.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Ann Intern Med. 2000 Feb 1;132(3):182-90 [10651598.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):159-67 [11172138.001]
  • [Cites] Medicine (Baltimore). 2002 May;81(3):213-27 [11997718.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Jul;162(1):64-7 [10903221.001]
  • [Cites] Thorax. 1999 Jul;54(7):567-71 [10377198.001]
  • [Cites] Clin Infect Dis. 1995 Sep;21(3):628-33 [8527555.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30 Suppl 1:S5-14 [10770911.001]
  • [Cites] Chest. 2001 Dec;120(6):1888-93 [11742918.001]
  • [Cites] Am Rev Respir Dis. 1987 Feb;135(2):504-9 [3813212.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Jan;155(1):72-80 [9001292.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Sep 1;164(5):847-51 [11549544.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):865-72 [10988097.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Oct;158(4):1221-9 [9769285.001]
  • [Cites] Lancet. 1998 Jan 24;351(9098):252-5 [9457095.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] AIDS. 1999 Feb 25;13(3):415-8 [10199233.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):347-55 [11273215.001]
  • (PMID = 15765925.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Colebunders R, Bastian I: A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis; 2000 Feb;4(2):97-107
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis.
  • Recommendations on the management of smear-negative pulmonary tuberculosis (TB) are still based on the behaviour of this disease in populations unaffected by the human immunodeficiency virus (HIV).
  • Studies prior to the HIV epidemic estimated that there were 1.22 cases of smear-negative and extra-pulmonary TB for each smear-positive case.
  • Patients with smear-negative pulmonary TB were found to be less infectious and to have a lower mortality, but a significant proportion (50%-71%) progressed to active disease justifying treatment.
  • Moreover, a wide variety of regimens also proved effective in the treatment of smear-negative disease in HIV-negative patients.
  • While apparently remaining less infectious than smear-positive cases, HIV-positive patients with smear-negative pulmonary TB are generally more immunocompromised, have more adverse drug reactions, and suffer higher mortality rates on treatment.
  • Clinical decision-making has also been complicated because HIV co-infection broadens the differential diagnoses of smear-negative pulmonary TB to include diseases such as Pneumocystis carinii pneumonia (PCP), pulmonary Kaposi's sarcoma, and Gram-negative bacteraemia.
  • Our approach to smear-negative pulmonary TB must therefore adapt to these changed parameters.
  • Management algorithms based on several features (clinical symptoms, response to antibiotic trials, smear investigations, and chest radiography) have been developed to improve case detection.
  • National tuberculosis programmes should also consider extending the use of rifampicin-based short-course chemotherapy (SCC) to new patients with smear-negative disease.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / drug therapy. Sputum / microbiology. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / drug therapy
  • [MeSH-minor] Antitubercular Agents / administration & dosage. Belgium / epidemiology. Diagnosis, Differential. Disease Outbreaks / prevention & control. Female. Humans. Incidence. Male. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694086.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antitubercular Agents
  • [Number-of-references] 83
  •  go-up   go-down


11. Dhrif AS, Kilani B, Ammari L, Kanoun F, Tiouri H, Ben Chaaben T: [AIDS-associated Kaposi's sarcoma: 22 cases]. Tunis Med; 2007 Jun;85(6):494-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS-associated Kaposi's sarcoma: 22 cases].
  • [Transliterated title] Maladie de Kaposi associee au SIDA: etude de 22 cas.
  • BACKGROUND: Kaposi's sarcoma is the most common acquired immune deficiency syndrome (AIDS)-associated malignancy.
  • Our aim was to analyse the epidemiological, clinical, therapeutic findings in AIDS patients with Kaposi's sarcoma.
  • METHODS: This was a retrospective chart review of AIDS patients with Kaposi's sarcoma diagnosed between 1991 and 2005.
  • Epidemiological data, the stage of human immunodeficiency virus's (HIV) infection, clinical characteristics of Kaposi's sarcoma, treatment rendered and outcome were collected.
  • They were 17 men and 5 females (sex-ratio=3.4/ 1) with a mean age of 33.6 years at the diagnosis of HIV infection.
  • The Kaposi's sarcoma appeared after a period varying between 0 and 10 years.
  • The Kaposi's sarcoma uncovered the infection in 5 cases.
  • The mean rate of CD4 was 216 21/mm3 at the diagnosis of Kaposi's sarcoma.
  • Mucocutaneous lesions were isolated in 12 cases and associated with visceral involvement in 10 cases; lung (10 cases), gastrointestinal tract (5 cases), lymphadenopathy (5 cases), liver (4 cases), spleen (2 cases).
  • Antiretroviral therapy was prescribed for 13 patients.
  • Six patients received chemotherapy and 3 others radiotherapy.
  • CONCLUSION: AIDS associated Kaposi's sarcoma is a severe condition because of visceral localisations and the field of immunodeficiency.
  • It requires a precocious diagnosis and collaboration.
  • The identification of HHV8 in the aetiopathogenic mechanism of Kaposi's sarcoma can lead to the development new therapeutic approaches.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Sarcoma, Kaposi / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. CD4 Lymphocyte Count. Female. Gastrointestinal Neoplasms / epidemiology. HIV Infections / epidemiology. Homosexuality, Male / statistics & numerical data. Humans. Liver Neoplasms / epidemiology. Lung Neoplasms / epidemiology. Male. Middle Aged. Retrospective Studies. Splenic Neoplasms / epidemiology. Substance Abuse, Intravenous / epidemiology. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644904.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


12. Shehan JM, Ahmed I: Angiosarcoma arising in a lymphedematous abdominal pannus with histologic features reminiscent of Kaposi's sarcoma: report of a case and review of the literature. Int J Dermatol; 2006 May;45(5):499-503
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma arising in a lymphedematous abdominal pannus with histologic features reminiscent of Kaposi's sarcoma: report of a case and review of the literature.
  • BACKGROUND: Despite common endothelial origins, angiosarcoma and Kaposi's sarcoma are clinically and histologically distinct vascular proliferations.
  • Similarly, tumors with the combined histologic features of angiosarcoma and Kaposi's sarcoma have rarely been described.
  • METHODS: We reviewed the literature on angiosarcoma arising in a lymphedematous abdominal pannus and evaluated an 81-year-old morbidly obese woman who had profound, long-standing edema of the lower abdominal wall in which an aggressive vascular tumor developed.
  • In addition, in our patient, sequential cutaneous sampling from different lesional sites demonstrated disparate histologic changes, ranging from those of classic Kaposi's sarcoma to high-grade angiosarcoma, to areas with combined features of the two tumors.
  • A polymerase chain reaction performed on lesional tissue was negative for human herpesvirus-8 DNA.
  • In addition, our case highlights the difficulty in differentiating histologically angiosarcoma from Kaposi's sarcoma in some situations, and demonstrates the value of close clinicopathologic correlation and sequential tissue sampling in evaluating problematic cases.
  • [MeSH-major] Edema. Hemangiosarcoma / diagnosis. Obesity, Morbid. Skin Neoplasms / diagnosis
  • [MeSH-minor] Abdomen / pathology. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Sarcoma, Kaposi / diagnosis

  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Dermatol. 2007 Jun;46(6):662 [17550576.001]
  • (PMID = 16700780.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


13. Chua R, Macdonald P: Kaposi's sarcoma occurring in a cardiac transplant patient on tacrolimus. Heart Lung Circ; 2006 Oct;15(5):340-1
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma occurring in a cardiac transplant patient on tacrolimus.
  • Kaposi's sarcoma is a relatively rare but potentially fatal malignancy which affects immunosuppressed individuals.
  • We report a case of cutneous Kaposi's sarcoma occurring in a cardiac transplant patient treated with tacrolimus.
  • [MeSH-major] Graft Rejection / drug therapy. Heart Transplantation. Immunosuppressive Agents / adverse effects. Sarcoma, Kaposi / etiology. Tacrolimus / adverse effects
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Follow-Up Studies. Heart Failure / surgery. Humans. Middle Aged. Risk Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781193.001).
  • [ISSN] 1443-9506
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


14. Sarjeant JM, Butany J, Cusimano RJ: Cancer of the heart: epidemiology and management of primary tumors and metastases. Am J Cardiovasc Drugs; 2003;3(6):407-21
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cardiac tumors, benign or malignant, are rare and most are benign.
  • Malignant cardiac tumors are usually sarcomas.
  • The pericardium can be the site of benign and malignant cardiac tumors, though metastatic tumors occur here far more commonly than do primary tumors.
  • Successful treatment for benign cardiac tumors is usually achieved by surgical resection.
  • Surgery for primary malignant tumors is, however, much less successful as complete resection is usually not possible.
  • Primary cardiac lymphoma may be successfully treated by chemotherapy.
  • Metastatic spread to the heart has been identified in approximately one-fifth of all patients who have metastatic cancer with lung carcinoma being the most common primary tumor.
  • Treatment varies depending on the pathology of the primary tumor.
  • However, the aim of treatment is usually symptomatic relief.
  • With the advent of AIDS, Kaposi's sarcoma and high grade B cell lymphomas have also been identified in cardiac tissue.
  • The aim of this article is to review the epidemiology, clinical presentation, pathology and treatment of cardiac tumors.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Carcinoid Heart Disease / diagnosis. Carcinoid Heart Disease / pathology. Hematologic Neoplasms / diagnosis. Hematologic Neoplasms / pathology. Humans. Neoplasm Metastasis. Pericardium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14728061.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 62
  •  go-up   go-down


15. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Antiretroviral agents have a propensity for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP) enzyme system.
  • Because many antineoplastic drugs are also metabolized by the CYP system, coadministration with cART could result in either drug accumulation with increased toxicity, or decreased efficacy of one or both classes of drugs.
  • Further research delineating the combined safety and pharmacokinetics of antiretrovirals and antineoplastic therapy is necessary.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Neoplasms / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


16. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
  • BACKGROUND: The relative roles of immunodeficiency, HIV viral load, and combination antiretroviral therapy (cART) in the onset of individual cancers have rarely been examined.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • The risk of Kaposi's sarcoma and non-Hodgkin lymphoma increased for current plasma HIV RNA greater than 100 000 copies per mL compared with patients with controlled viral load (RR 3.1, 95% CI 2.3-4.2, p<0.0001; and 2.9, 2.1-3.9, p<0.0001, respectively), whereas cART was independently associated with a decreased incidence (0.3, 0.2-0.4, p<0.0001; and 0.8, 0.6-1.0, p=0.07, respectively).
  • The risk of anal cancer increased with the time during which the CD4 count was less than 200 cells per microL (1.3 per year, 1.2-1.5; p=0.0001), and viral load was greater than 100 000 copies per mL (1.2 per year, 1.1-1.4, p=0.005).
  • INTERPRETATION: cART would be most beneficial if it restores or maintains CD4 count above 500 cells per microL, thereby indicating an earlier diagnosis of HIV infection and an earlier treatment initiation.
  • FUNDING: Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.
  • [MeSH-minor] Adolescent. Adult. Aged. CD4 Lymphocyte Count. Cohort Studies. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Prospective Studies. Risk Factors. Viral Load


17. Lavolé A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer; 2006 Jan;51(1):1-11
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer, a new challenge in the HIV-infected population.
  • HIV infection predisposes patients to AIDS-defining malignancies, some of which, such as Kaposi's sarcoma and non-Hodgkin lymphoma, can affect the lungs.
  • In 1996, AIDS-related mortality started to fall sharply in industrialized countries following the introduction of highly active antiretroviral treatments (HAART).
  • This was accompanied by an increase in the proportion of deaths attributable to non AIDS-defining solid tumors, and especially lung cancer (LC).
  • The average age of HIV-infected patients at LC diagnosis is about 45 years.
  • Most patients are symptomatic at diagnosis and have only mild or moderate immunosuppression.
  • Adenocarcinoma is the most frequent histologic type.
  • Data on the efficacy and toxicity of chemotherapy in this setting are rare and rather imprecise.
  • Surgery remains the reference treatment for localized disease in patients with adequate functional status and general health, regardless of their immune status.
  • Prospective clinical trials are needed to define the optimal LC treatment strategies in HIV-infected patients.
  • [MeSH-major] HIV Infections / complications. Lung Neoplasms / etiology






Advertisement